The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 22 August 2006, www.theannals.com, DOI 10.1345/aph.1H116.
 The Annals of Pharmacotherapy: Vol. 40, No. 10, pp. 1834-1837. DOI 10.1345/aph.1H116
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thormahlen, G. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thormahlen, G. M

DRUG INFORMATION ROUNDS

Paroxetine Use During Pregnancy: Is it Safe?

Genine M Thormahlen, PharmD

Drug Information Specialist, Department of Pharmacy Practice, The University of Montana Drug Information Service, 32 Campus Dr., #1522, Missoula, MT 59812-1522, fax 406/243-5256, genine.thormahlen{at}umontana.edu

Reprints: Dr. Thormahlen

OBJECTIVE: To evaluate the literature assessing the neonatal risks of antepartum paroxetine use.

DATA SOURCES: MEDLINE (1966-August 2006) and International Pharmaceutical Abstracts (1970-August 2006) searches were performed. Key search terms included paroxetine, SSRI, pregnancy, malformations, neonate, and fetus.

DATA SYNTHESIS: Selective serotonin-reuptake inhibitors (SSRIs) are associated with neonatal withdrawal symptoms such as respiratory distress, irritability, lethargy, and tremors. In a cohort study, 30% of infants exposed to SSRIs had poor neonatal adaptation, compared with 9% of controls (p = 0.018). Some reports indicate that paroxetine is more commonly associated with neonatal withdrawal than other SSRIs. Recently, paroxetine was associated with a 1.82-fold (95% CI 1.17 to 2.82) increased risk of congenital malformations compared with other antidepressants. Other SSRIs were also associated with an increased risk of congenital malformations; however, the results were not statistically significant. Literature supporting these findings includes case reports and case-control or cohort studies. The Food and Drug Administration recommendations regarding paroxetine use during pregnancy have been added to the labeling information.

CONCLUSIONS: Paroxetine may cause adverse outcomes in the neonate when used during pregnancy and should be discontinued in women who are pregnant or trying to become pregnant. The risks and benefits of other antidepressant use should be analyzed on an individual basis.

Key Words: malformations, paroxetine, pregnancy, selective serotonin-reuptake inhibitors

Published Online, August 22, 2006. www.theannals.com, DOI 10.1345/aph.1H116


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
W. Wood and A. Einarson
Comment: Paroxetine Use During Pregnancy: Is It Safe?
Ann. Pharmacother., December 1, 2006; 40(12): 2281 - 2282.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.